{"title": "Increased muscle mass improves response to cancer treatment", "title_detail": {"type": "text/plain", "language": null, "base": "https://www.sciencedaily.com/rss/health_medicine/immune_system.xml", "value": "Increased muscle mass improves response to cancer treatment"}, "links": [{"rel": "alternate", "type": "text/html", "href": "https://www.sciencedaily.com/releases/2019/03/190304100040.htm"}], "link": "https://www.sciencedaily.com/releases/2019/03/190304100040.htm", "summary": "Researchers have found that sarcopenia, a condition characterized by decreased skeletal muscle mass, is strongly associated with poor treatment outcomes in lung cancer patients in response to programed death-1 (PD-1)-inhibitor therapy. However, as well as being useful for identifying patients likely to benefit from this type of therapy, early identification and treatment of sarcopenia may improve the long-term survival rates of a larger group of patients.", "summary_detail": {"type": "text/html", "language": null, "base": "https://www.sciencedaily.com/rss/health_medicine/immune_system.xml", "value": "Researchers have found that sarcopenia, a condition characterized by decreased skeletal muscle mass, is strongly associated with poor treatment outcomes in lung cancer patients in response to programed death-1 (PD-1)-inhibitor therapy. However, as well as being useful for identifying patients likely to benefit from this type of therapy, early identification and treatment of sarcopenia may improve the long-term survival rates of a larger group of patients."}, "published": "Mon, 04 Mar 2019 10:00:40 EST", "published_parsed": [2019, 3, 4, 15, 0, 40, 0, 63, 0], "id": "https://www.sciencedaily.com/releases/2019/03/190304100040.htm", "guidislink": false}